Emerging research suggest this peptide, a dual agonist targeting both incretin and another hormone, appears to provide a notable advancement for body management . Initial clinical trials have indicated substantial losses in visceral fat , possibly outperforming existing obesity treatments. However , more assessment is necessary to completely determ